Xtandi Launch Meetings - Iridium Kankernetwerk

INVITATION
Astellas kindly invites you
to the Belgian
Register now via
www.xtandilaunch.be
This meeting is supported by
Xtandi Launch Meetings:
New treatment options in mCRPC:
Where does Xtandi® t in?
Organisation: Ismar Healthcare
Leopoldplein 39 bus 1, 2500 Lier, Belgium
Iris Schrooten: [phone], Kristof Willems: [phone]
www.ismar.com
This meeting is supported by
BE/XTD/14/0021
Tuesday 2 December (meeting in Dutch)
Lamot • Mechelen
Van Beethovenstraat 8-10
2800 Mechelen
www.lamot-mechelen.be
Dr. Piet Dirix (radiation oncologist)
Prof. dr. Steven Joniau (urologist)
Dr. Daisy Luyten (medical oncologist)
Monday 15 December (meeting in French)
Château de Colonster • Liège
Université de Liège, Allée des Érables
4000 Liège
www.colonster.ulg.ac.be
Dr. Olivier De Hertogh (radiation oncologist)
Prof. dr. Brieuc Sautois (medical oncologist)
Prof. dr. David Waltregny (urologist)
Wednesday 14 January (meeting in French)
Loungeatude • Ottignies-Louvain-la-Neuve
Place Polyvalente (derrière La Ferme du Biéreau),
1348 Ottignies Louvain-la-Neuve
www.loungeatude.be
Dr. Marco Gizzi (medical oncologist)
Dr. Sam Palumbo (radiation oncologist)
Prof. dr. Bertrand Tombal (urologist)
DATA, LOCATIONS AND FACULTIES
Tuesday 20 January (meeting in French)
Le Palais De Plume • Ittre
Rue Haute 8
1460 Ittre
www.lepalaisdeplume.com
Dr. Richard Burette (radiation oncologist)
Prof. dr. Thierry Roumeguère (urologist)
Dr. Thierry Gil (medical oncologist)
Wednesday 21 January (meeting in Dutch)
Auberge du Pêcheur • Sint-Martens-Latem
Pontstraat 41
9831 Deurle - Sint-Martens-Latem
www.auberge-du-pecheur.be
Prof. dr. Gert De Meerleer (radiation oncologist)
Dr. Peter Schatteman (urologist)
Dr. Filip Van Aelst (medical oncologist)

Only a few years ago, the therapeutic options for men with advanced prostate cancer were quite limited.
Patients with distant recurrences were mostly treated with androgen-deprivation therapy; those with
metastatic castration-resistant prostate cancer (mCRPC) received chemotherapy.
Improved imaging techniques however, have created the new disease entity ‘oligometastatic disease‘ in
which only a limited number of regions are involved. Is local treatment of these metastatic spots a valuable
option for these patients?
Another important development of the last few years is the increasing therapeutic arsenal to manage
patients with mCRPC, including the androgen receptor targeting agent enzalutamide. From December
onwards, enzalutamide will be reimbursed in Belgium. With the new treatment options, new questions arise.
How can we reach the goal of administering the right treatment to the right patient at the right time?
This meeting will provide insight in local therapy for recurrent prostate cancer and oligometastatic disease.
The focus will be on best practice for treating men with mCRPC, with an emphasis on enzalutamide as
second-line option after docetaxel.
Interested to participate in one of these meetings?
PROGRAMME
New treatment options in mCRPC:
Where does Xtandi® t in?
19.00-19.30 Welcome drink & appetisers
19.30-19.45 Introduction by Astellas
19.45-20.15 Radiotherapy for recurrent prostate cancer
20.15-20.45 Enzalutamide in clinical trials: Efficacy, tolerability and quality of life
20.45-21.15 Enzalutamide in clinical practice: Discussion of clinical cases
21.15 Walking dinner
This meeting is supported by
Please register via: www.xtandilaunch.be

Only a few years ago, the therapeutic options for men with advanced prostate cancer were quite limited.
Patients with distant recurrences were mostly treated with androgen-deprivation therapy; those with
metastatic castration-resistant prostate cancer (mCRPC) received chemotherapy.
Improved imaging techniques however, have created the new disease entity ‘oligometastatic disease‘ in
which only a limited number of regions are involved. Is local treatment of these metastatic spots a valuable
option for these patients?
Another important development of the last few years is the increasing therapeutic arsenal to manage
patients with mCRPC, including the androgen receptor targeting agent enzalutamide. From December
onwards, enzalutamide will be reimbursed in Belgium. With the new treatment options, new questions arise.
How can we reach the goal of administering the right treatment to the right patient at the right time?
This meeting will provide insight in local therapy for recurrent prostate cancer and oligometastatic disease.
The focus will be on best practice for treating men with mCRPC, with an emphasis on enzalutamide as
second-line option after docetaxel.
Interested to participate in one of these meetings?
PROGRAMME
New treatment options in mCRPC:
Where does Xtandi® t in?
19.00-19.30 Welcome drink & appetisers
19.30-19.45 Introduction by Astellas
19.45-20.15 Radiotherapy for recurrent prostate cancer
20.15-20.45 Enzalutamide in clinical trials: Efficacy, tolerability and quality of life
20.45-21.15 Enzalutamide in clinical practice: Discussion of clinical cases
21.15 Walking dinner
This meeting is supported by
Please register via: www.xtandilaunch.be

INVITATION
Astellas kindly invites you
to the Belgian
Register now via
www.xtandilaunch.be
This meeting is supported by
Xtandi Launch Meetings:
New treatment options in mCRPC:
Where does Xtandi® t in?
Organisation: Ismar Healthcare
Leopoldplein 39 bus 1, 2500 Lier, Belgium
Iris Schrooten: [phone], Kristof Willems: [phone]
www.ismar.com
This meeting is supported by
BE/XTD/14/0021
Tuesday 2 December (meeting in Dutch)
Lamot • Mechelen
Van Beethovenstraat 8-10
2800 Mechelen
www.lamot-mechelen.be
Dr. Piet Dirix (radiation oncologist)
Prof. dr. Steven Joniau (urologist)
Dr. Daisy Luyten (medical oncologist)
Monday 15 December (meeting in French)
Château de Colonster • Liège
Université de Liège, Allée des Érables
4000 Liège
www.colonster.ulg.ac.be
Dr. Olivier De Hertogh (radiation oncologist)
Prof. dr. Brieuc Sautois (medical oncologist)
Prof. dr. David Waltregny (urologist)
Wednesday 14 January (meeting in French)
Loungeatude • Ottignies-Louvain-la-Neuve
Place Polyvalente (derrière La Ferme du Biéreau),
1348 Ottignies Louvain-la-Neuve
www.loungeatude.be
Dr. Marco Gizzi (medical oncologist)
Dr. Sam Palumbo (radiation oncologist)
Prof. dr. Bertrand Tombal (urologist)
DATA, LOCATIONS AND FACULTIES
Tuesday 20 January (meeting in French)
Le Palais De Plume • Ittre
Rue Haute 8
1460 Ittre
www.lepalaisdeplume.com
Dr. Richard Burette (radiation oncologist)
Prof. dr. Thierry Roumeguère (urologist)
Dr. Thierry Gil (medical oncologist)
Wednesday 21 January (meeting in Dutch)
Auberge du Pêcheur • Sint-Martens-Latem
Pontstraat 41
9831 Deurle - Sint-Martens-Latem
www.auberge-du-pecheur.be
Prof. dr. Gert De Meerleer (radiation oncologist)
Dr. Peter Schatteman (urologist)
Dr. Filip Van Aelst (medical oncologist)